newswire, breaking biotechnology and pharma news

Wednesday, December 1, 2010

Q&A Interview with Fast Growing Biotech Products Company UV Flu Technologies (OTCBB: UVFT)

December 1, 2010 ( Newswire, ) - and its leading Biotech investor portal release a Q&A with biotech company UV Flu Technologies, Inc. (OTCBB: UVFT). Mr. John J. Lennon, President & CEO, discusses recent developments with the company's air purifying technology, ViraTech UV-400.
To give investors an introduction, UV Flu Technologies Inc. (OTCBB: UVFT) develops and manufactures technologies within the Indoor Air Quality (IAQ) industry sector, with your primary product, the ViraTech™ UV-400 model that purifies indoor air by killing bacteria, including superbugs such as NDM-1.
As global awareness increases for the need for better air and water quality technology, your company is aggressively marketing its technology to both consumers and industry. Can you give some hi- lights of what's in the pipeline?
A: Our Company is building a brand. The inadequacy of previous entrants in the air-purifier marketplace makes our job all the more important. Companies in the past, and present, continue to sell millions of air purifiers, with technology that just doesn't work in the residential marketplace. Our products are designed to work with almost no maintenance required. As long as the green light is on, our UV-400 is killing contaminants! We are designing a model specifically for the residential marketplace that we believe will be a category killer! It will have all the killing capabilities of our UV-400, at a lower price point. It will have the capability to kill, and trap, will be the most attractive air purifier in the world, and will have independent, FDA/EPA lab certified test results to support every claim. It will also have 3-4 times the coverage of a typical HEPA based unit, at the same price.
We will also purchase higher volume models to extend our lines on the commercial side.
According to your website," Independent EPA and FDA certified laboratory testing confirms the system kills airborne bacteria at rates ranging from 99.2% to more than 99.99% on a first-pass basis. In actual operation multiple passes through the unit will occur, producing average removal rates that far exceed 99.2%." How does this compare to competition in terms of cost and efficiency?
A: Interestingly enough, there are very few units in the world today that actually kill contaminants. Over 95% of air purifiers on the market today capture, but don't kill contaminants. They rely on electrostatic, or HEPA filter technology, which captures, but doesn't kill particulates. All of these products, if filters or plates are not replaced or cleaned on a regular basis, can produce air that is actually dirtier than leaving the unit off. The filters become a “petrie" dish, where bacterial or viral colonies can grow in the filter.
The UV-400 has a kill chamber, which uses Germicidal UV light to kill organic contaminants. Independent lab tests have verified that the killing ability is almost identical, whether it is bacteria, or viruses. The unit can cover a space of up to 7-900 sq ft, while still passing the air 3X per hour. Competing HEPA or electrostatic products can cover 150-200 sq ft, when the filter is clean-less when the filter is dirty. It would typically take 4 HEPA filters to cover the same space. These products typically need $100-150 annually in new filters, as well.
The company has completed the design of its second product, a smaller, lower cost version of the ViraTech™ UV-400. Can you give us some insight into the markets and applications for it?
A: One residential electrostatic air purifier product sold 3 million units at $400 apiece, before it was pulled from the market, due to its inability to clean the air. We think there is an international market potential for our product of several hundred thousand units per year. The market would be geared to the market for bedrooms, apartments, hotel room, and small offices, where price points, and space coverage requirements are lower.
According to a recent report by Global Industry Analysts, Inc., demand for air filters in developing countries will outpace growth in mature markets such as US, European, and Japan. By 2015, China will supplant Japan to become the second largest market for air filter equipment behind United States. What are the company's plans to participate in the global market?
A: The Company already has the international markets in its sights. Air quality in developing markets, including China, is considerably worse than in this country. The Company has begun shipping units to Europe, which suffers from epidemic rates of HAI's, or hospital associated infections, like MRSA, and plans on having distribution to China by mid-year 2011.
About UV Flu Technologies, Inc. (OTCBB: UVFT).
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at:
Research Report by Michael Williams, Biotech Stock Pick:
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at:
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
SOURCE: UV Flu Technologies, Inc.
About : is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : is a global meeting place for investors and industry following the sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Research more biotech stocks at the Biotech stocks Directory:
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:  
For Additional Information about Biotech portals:

No comments:

Post a Comment